JP2022511866A5 - - Google Patents

Info

Publication number
JP2022511866A5
JP2022511866A5 JP2021532219A JP2021532219A JP2022511866A5 JP 2022511866 A5 JP2022511866 A5 JP 2022511866A5 JP 2021532219 A JP2021532219 A JP 2021532219A JP 2021532219 A JP2021532219 A JP 2021532219A JP 2022511866 A5 JP2022511866 A5 JP 2022511866A5
Authority
JP
Japan
Prior art keywords
nucleotides
nucleotide
modified
rnai construct
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021532219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511866A (ja
JP7814932B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065294 external-priority patent/WO2020123410A1/en
Publication of JP2022511866A publication Critical patent/JP2022511866A/ja
Publication of JP2022511866A5 publication Critical patent/JP2022511866A5/ja
Priority to JP2026017347A priority Critical patent/JP2026074186A/ja
Application granted granted Critical
Publication of JP7814932B2 publication Critical patent/JP7814932B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021532219A 2018-12-10 2019-12-09 化学修飾されたRNAiコンストラクト及びその使用 Active JP7814932B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026017347A JP2026074186A (ja) 2018-12-10 2026-02-04 化学修飾されたRNAiコンストラクト及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862777677P 2018-12-10 2018-12-10
US62/777,677 2018-12-10
PCT/US2019/065294 WO2020123410A1 (en) 2018-12-10 2019-12-09 CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026017347A Division JP2026074186A (ja) 2018-12-10 2026-02-04 化学修飾されたRNAiコンストラクト及びその使用

Publications (3)

Publication Number Publication Date
JP2022511866A JP2022511866A (ja) 2022-02-01
JP2022511866A5 true JP2022511866A5 (cg-RX-API-DMAC7.html) 2022-12-14
JP7814932B2 JP7814932B2 (ja) 2026-02-17

Family

ID=69024730

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532219A Active JP7814932B2 (ja) 2018-12-10 2019-12-09 化学修飾されたRNAiコンストラクト及びその使用
JP2026017347A Pending JP2026074186A (ja) 2018-12-10 2026-02-04 化学修飾されたRNAiコンストラクト及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026017347A Pending JP2026074186A (ja) 2018-12-10 2026-02-04 化学修飾されたRNAiコンストラクト及びその使用

Country Status (13)

Country Link
US (1) US20220049252A1 (cg-RX-API-DMAC7.html)
EP (1) EP3894554A1 (cg-RX-API-DMAC7.html)
JP (2) JP7814932B2 (cg-RX-API-DMAC7.html)
CN (2) CN119061010A (cg-RX-API-DMAC7.html)
AU (2) AU2019395341B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011043A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122393A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001490A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191630A1 (cg-RX-API-DMAC7.html)
IL (1) IL283550A (cg-RX-API-DMAC7.html)
MX (1) MX2021006745A (cg-RX-API-DMAC7.html)
SG (1) SG11202105900UA (cg-RX-API-DMAC7.html)
WO (1) WO2020123410A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE068630T2 (hu) 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
CA3121510A1 (en) 2018-12-10 2020-06-18 Amgen Inc. Rnai constructs for inhibiting pnpla3 expression and methods of use thereof
JP7827623B2 (ja) * 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド LPA発現を阻害するためのRNAiコンストラクト及び方法
US20230279399A1 (en) * 2020-06-01 2023-09-07 Amgen Inc. Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
EP4196584A2 (en) 2020-08-13 2023-06-21 Amgen Inc. Rnai constructs and methods for inhibiting marc1 expression
KR20230104200A (ko) * 2020-11-05 2023-07-07 암젠 인크 LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
BR112023014443A2 (pt) * 2021-01-30 2024-01-23 E Therapeutics Plc Ácidos nucleicos contendo nucleotídeos abásicos
CN116829717A (zh) * 2021-01-30 2023-09-29 e-生物有限公司 含有无碱基核苷酸的核酸
EP4176061A1 (en) * 2021-01-30 2023-05-10 E-Therapeutics plc Nucleic acids containing abasic nucleotides
US20250034561A1 (en) * 2021-02-18 2025-01-30 Oneglobe Holdings Limited Novel Compositions for Conjugating Oligonucleotides and Carbohydrates
CA3225054A1 (en) * 2021-07-08 2023-02-12 Sun Woo Hong Rnai agent targeting marc1 gene, and use thereof
CA3232053A1 (en) * 2021-10-08 2023-04-13 E-Therapeutics Plc Nucleic acids containing abasic nucleosides
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
CN118401665A (zh) * 2021-12-03 2024-07-26 中天(上海)生物科技有限公司 具有高稳定性和基因沉默活性的小干扰rna分子的修饰模式
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
WO2023207615A1 (zh) * 2022-04-26 2023-11-02 南京明德新药研发有限公司 一类含由天然核苷酸组成突出端的双链RNAi化合物
CA3262515A1 (en) 2022-07-25 2024-02-01 Amgen Inc. ARNI CONSTRUCTIONS AND METHODS FOR INHIBITING FAM13A EXPRESSION
KR20250043472A (ko) * 2022-07-27 2025-03-28 이-테라퓨틱스 피엘씨 핵산 화합물
WO2024023256A1 (en) * 2022-07-27 2024-02-01 E-Therapeutics Plc Nucleic acid compounds
WO2024061185A1 (zh) * 2022-09-20 2024-03-28 上海舶望制药有限公司 特定修饰的RNAi试剂和组合物
WO2024081954A2 (en) * 2022-10-14 2024-04-18 Sanegene Bio Usa Inc. Small interfering rna targeting c3 and uses thereof
US20260209772A1 (en) * 2022-12-23 2026-07-23 Eli Lilly And Company Novel rna therapeutics and uses thereof
WO2024140101A1 (zh) * 2022-12-28 2024-07-04 北京炫景瑞医药科技有限公司 修饰的双链寡核苷酸分子、修饰的双链寡核苷酸缀合物及其用途
CN122167331A (zh) 2023-05-19 2026-06-09 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
EP4722363A1 (en) * 2023-05-24 2026-04-08 Yun Ho Bio Co., Ltd Rnai agent for inhibiting angptl3 expression and use thereof
WO2025113470A1 (en) * 2023-11-27 2025-06-05 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of transthyretin (ttr)
WO2025232837A1 (zh) * 2024-05-08 2025-11-13 深圳信立泰药业股份有限公司 经修饰的siRNA及其制备方法和用途
WO2025260042A1 (en) 2024-06-14 2025-12-18 Amgen Inc. Rnai constructs and methods for inhibiting cnr1 expression
WO2026002138A1 (zh) * 2024-06-27 2026-01-02 成都新泽利医药科技有限公司 特定修饰的双链寡核苷酸及其组合物
WO2026131490A1 (en) * 2024-12-20 2026-06-25 Ribocure Pharmaceuticals Ab Oligonucleotide, oligonucleotide conjugate and composition, and use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20120004160A1 (en) * 2009-02-19 2012-01-05 Glaxo Group Ltd. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
US9796974B2 (en) * 2011-11-18 2017-10-24 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso

Similar Documents

Publication Publication Date Title
JP2023504744A5 (cg-RX-API-DMAC7.html)
JP2023537943A5 (cg-RX-API-DMAC7.html)
JP6452614B2 (ja) オリゴヌクレオチドコンジュゲート
JP6060178B2 (ja) 高効率のナノ粒子型二本鎖オリゴrna構造体およびその製造方法
WO2023284763A1 (zh) 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
KR101862349B1 (ko) 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법
JP2024105284A5 (cg-RX-API-DMAC7.html)
JP2009513144A5 (cg-RX-API-DMAC7.html)
CA3189861A1 (en) Dux4 inhibitors and methods of use thereof
US11390867B2 (en) G-quadruplex-containing antisense oligonucleotides
EA015563B1 (ru) Короткая внутренне сегментированная интерферирующая рнк
CN117916376A (zh) 信号可激活核酸复合物
TW202421784A (zh) 用於抑制fxi表現之多核酸分子、醫藥組合物及其用途
KR20240099201A (ko) Pcsk9를 표적화하는 다중핵산 분자 및 이의 용도
JP2022550979A5 (cg-RX-API-DMAC7.html)
CN118202048A (zh) 条件可激活核酸复合物
WO2023284559A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2024137700A2 (en) Polynucleic acid molecules targeting agt and uses thereof
JP2024537098A5 (cg-RX-API-DMAC7.html)
TW202546233A (zh) 用於抑制lp(a)或apoc3之表現的多核酸分子、醫藥組合物及其用途
WO2025016342A1 (zh) 靶向血管紧张素原的寡核苷酸及其用途
CN120077134A (zh) 靶向apoc3的多核酸分子及其用途
JP2025512771A5 (cg-RX-API-DMAC7.html)
WO2023168202A2 (en) Certain dux4 inhibitors and methods of use thereof
EP4153749A1 (en) Method for treating cyclophilin a associated diseases